Conatus reports 4Q loss

SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Wednesday reported a loss of $4.4 million in its fourth quarter.

The San Diego-based company said it had a loss of 15 cents per share.

The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.

The biotechnology company posted revenue of $8.8 million in the period, which fell short of Street forecasts. Five analysts surveyed by Zacks expected $9.6 million.

For the year, the company reported that its loss narrowed to $17.4 million, or 61 cents per share. Revenue was reported as $35.4 million.

Conatus shares have risen 49 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $6.88, a climb of 59 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CNAT at https://www.zacks.com/ap/CNAT